A Vaxxing Question

In 1956 German pharmaceutical company Chemie Grünenthal GmbH, licensed a new experimental drug designed to treat colds, flu, nausea and morning sickness. Known as Distaval in the UK, Distillers Biochemicals Ltd declared the drug could ‘be given with complete safety to pregnant women and nursing mothers without adverse effect on mother or child’ – a basic pre-requisite for licensing a drug.

While forty-nine countries licensed the drug under multiple different names, the then head of the FDA Dr. Frances Kelsey, a physician-pharmacologist with a profound interest in fetal development, refused authorization for use in the US market due to her concerns about the lack of evidence regarding the drug’s safety.

The drug was also known as Thalidomide.

Sixty-five years on and the stringent safety measures brought in to avoid another scandal on the scale of Thalidomide have been swept aside in order to fast track the approval of experimental mRNA vaccines. This is in spite of concerns voiced by (among others) Dr Wolfgang Wodarg and Dr Michael Yeadon who petitioned the European Medical Agency (EMA) with a Administrative/Regulatory Stay Of Action in regard to the BioNtech/Pfizer study on BNT162b – not just in regard to concerns about pregnant women, the foetus and infertility – but also in regard to the effect of the mRNA vaccines on those with prior immunity, for whom immunization could lead to a hyperinflammatory response, a cytokine storm, and a generally dysregulation of the immune system that allows the virus to cause more damage to their lungs and other organs of their body.

No previous research into treating illness or disease with messenger RNA or mRNA vaccines has been successful and this is the first time mRNA vaccines have been used on humans.

The concerns of Yeadon, Wodarg and others appear to be borne out by data from the King’s College Zoe app that records adverse events from the mRNA vaccines. Taken from a pool of 700,000, data reveals that 12.2% of those vaccinated with the Pfizer jab experienced adverse events or side effects, a number which tripled to 35.7% for those with prior immunity. Adverse events from the Oxford/AstraZeneca jab were already high at 31.9% but increased to 52.7% for people with immunity.

Ellie Barnes, professor of hepatology and immunology at Oxford University and a member of the UK Coronavirus Immunology Consortium referred to the discovery – that when you’ve had a COVID-19 infection your T-cells become activated and become memory T cells – as ‘emerging’ as though this was something revelatory. Yet the dangers of over-immunization had been flagged up multiple times and well before vaccine rollout.

It gets worse.

In spite of additional research from New York’s Mount Sinai Hospital and the University of Maryland which indicated that those who had previously developed Covid-19 were effectively already immune and wouldn’t need a second dose (arguably they didn’t need the first dose if they already had immunity), Eleanor Riley, professor of infectious diseases at Edinburgh University said that ‘Incorporating this into a mass vaccination program, may be logistically complex’, adding ‘it may be safer overall to ensure everyone gets two doses’.

May be safer? Many in the study group had already had an adverse event from the first dose, so how could it be ‘safer’ when second doses have been shown to increase the adversity of an event.

And how is it logistically complex to notify those who have already experienced an adverse event? The medical data of the 700,000 patients has already been logged into the Zoe App system, otherwise the Zoe App wouldn’t be able to differentiate between those with or without prior immunity. Therefore, those with prior immunity from having had Covid-19 – or those for whom an adverse event would perhaps indicate prior immunity – can be notified that there is no need for a second dose.

Moreover, why on earth aren’t people tested for prior immunity before taking any vaccination considering the concerns associated with over-immunization?

Alarming data is also emerging from the Yellow Card Scheme.

Read the Whole Article